Healthcare and life sciences investment firm Foresite Capital has closed its biggest fund to date by collecting $668m for its fourth fund in seven years.
Foresite was only created in 2011, and closed its debut fund on $100m two years later.
The firm wasted no time in following that with a $300m second fund in 2014, and collected $450m for Fund III in 2015.
The firm now has $2bn in assets under management, with an aim to invest in private and public companies that develop innovative therapeutics, discovery and data science tools, and new approaches to clinical care.
Foresite founder and CEO Jim Tananbaum said, “At Foresite Capital we’ve brought together a unique value proposition for our portfolio companies.
“We not only provide capital from seed to public stage, but also a multidisciplinary team of scientists, clinicians, analysts and engineers who collaborate to seek the best data-driven decisions.
“The ability to ingest and derive meaning from massive amounts of complex information is a critical success factor in healthcare investing.”
Portfolio investments to date include 10x Genomics, Intarcia Therapeutics and Aerie Pharmaceuticals.
Copyright © 2018 AltAssets